Aegerion Shares Rise on Report of High Cholesterol Drug
This article is for subscribers only.
Aegerion Pharmaceuticals Inc. rose after a U.S. regulatory staff report said a plan to manage the risks of the company’s drug supports its approval in adults with the most life-threatening forms of severely high cholesterol.
Aegerion gained 9.4 percent to $17.46 at the close of New York trading following the Food and Drug Administration’s staff report today. An advisory panel will meet Oct. 17 on the medicine lomitapide, Cambridge, Massachusetts-based Aegerion’s lead product candidate, with the FDA scheduled to make a final decision by the end of December.